Abstract
Psoriasis is a chronic-inflammatory skin disease. In case of moderate and severe psoriasis (approximately 20-30 % of all patients), systemic treatment is necessary. Recent findings regarding the pathomechanism of psoriasis led to the development of targeting molecules, so-called biologics. These biotechnical products are able to selectively block mediators that are relevant for inflammation or to block the interaction between cells, imitating or inhibiting natural proteins.
Translated title of the contribution | Treatment of psoriasis with biologics |
---|---|
Original language | German |
Journal | Haut |
Volume | 18 |
Issue number | 1 |
Pages (from-to) | 6-9 |
Number of pages | 4 |
ISSN | 0938-2216 |
Publication status | Published - 02.2007 |
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)